Early detection for colorectal cancer: New aspects in fecal occult blood screening

Journal of Surgical Oncology

Volumn 75, Issue 3, 2000, Pages 220-226

  Ottó, Szabolcs ^a,b   Eckhardt, Sándor ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b NONE   (Hungary)

Author keywords

Colorectal cancer; FOB test; Hemoglobin degradation products; Immunochemical tests; Screening

Indexed keywords

CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; LIFESTYLE; MASS SCREENING; OCCULT BLOOD; POLYPECTOMY; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0033697293     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9098(200011)75:3<220::AID-JSO14>3.0.CO;2-8     Document Type: Review

References (152)

1. Estimates of costs and effects of screening for colorectal cancer in the United States
2. Cancer Statistics. 1994
3. Cancer Statistics. 1998
4. Overview of the epidemiology of colorectal cancer
5. Screening for colorectal cancer
6. Colonic tumors
7. Colorectal cancer: Detection, treatment, and rehabilitation
8. Screening for colorectal cancer
9. Colon cancer screening: Beyond efficacy
10. Colonic tumors
11. Screening for asymptomatic colorectal cancer
12. Colorectal cancer screening: Recommendations of the US preventive services task force
13. Improving the effectiveness of fecal occult blood screening for colorectal cancer
14. Colorectal cancer. A blueprint for disease control through screening by primary care physicians
15. Delay in diagnosis of colorectal cancer
16. Colorectal cancer: Incidence, delay in diagnosis and stage of disease
17. Screening for colorectal cancer
18. Fecal occult blood screening for colorectal cancer
19. Fecal occult blood screening and reduction of colorectal cancer mortality: A case-control study
20. Randomized controlled trial of fecal-occult-blood screening for colorectal cancer
21. Randomized study of screening for colorectal cancer with fecal-occult-blood test
22. Effect of fecal occult blood testing on mortality from colorectal cancer: A case-control study
23. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study
24. J Cancer Screening for colorectal cancer by immunochemical fecal occult blood testing
25. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
26. Reducing mortality from colorectal cancer by screening for fecal occult blood
27. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997
28. New screening guidelines for colorectal cancer
29. Revisions in American Cancer Society recommendations for the early detection of colorectal cancer
30. Colorectal cancer screening comes of age
31. American Cancer Society guidelines for the early detection of cancer
32. Acceptability of opportunistic testing for fecal occult blood
33. Screening for colorectal cancer
34. Colorectal cancer prevention. An approach to increasing compliance in a fecal occult blood test screening program
35. Heads or tails in a positive fecal occult blood test
36. A systematic review of the effects of screening for colorectal cancer using the fecal occult blood test, Hemoccult
37. Population screening for colorectal carcinoma with fecal-occult blood testing
38. Screening for colon cancer in Germany
39. A critical review of cancer screening programs in Japan
40. Mass screening for colorectal cancer in Japan
41. An evaluation of mass screening using fecal occult blood test for colorectal cancer in Japan: A case-control study
42. The potential of new screening tests for colorectal cancer to enhance patient acceptability
43. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer
44. Screening for colorectal cancer
45. Occult-blood screening for colorectal carcinoma: The risks
46. Occult-blood screening for colorectal carcinoma: The yield and costs
47. The economic of screening for colorectal cancer
48. Cost benefits of Hemoccult screening for colorectal carcinoma
49. How to perform the fecal occult blood test
50. Occult blood screening for colorectal carcinoma: A critical review
51. Occult blood screening of Canadians - Wise or unwise?
52. Hemoccult test-screening: Pro 'Kontroversen in der Gastroenterologie'
53. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial
54. Distribution of large-bowel cancers detected by occult blood test in asymptomatic patients
55. Mass screening for colorectal cancer by testing fecal occult blood
56. Evaluation of possibilities for mass screening for colorectal cancer with Hemoccult fecal blood test
57. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects
58. More on fecal occult blood testing and colon cancer
59. Detection and diagnosis of colorectal cancer
60. Screening for symptomless colorectal cancer by testing for occult blood in general practice
61. The pros and cons of fecal occult blood testing for colorectal neoplasms
62. Cancer statistics, 2000
63. Screening for colorectal cancer
64. Diagnostic testing following fecal occult blood screening in elderly
65. Screening for colorectal cancer: An overview
66. Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia
67. Screening and surveillance for colorectal cancer
68. Detecting colon cancer
69. Screening for colorectal cancer in a Hungarian county
70. Determination of factors responsible for the declining incidence of colorectal cancer
71. The relation of age, race, and gender to the subsite location of colorectal cancer
72. Diagnosis of large bowel cancer in the asymptomatic patient
73. Sensitivity and reproducibility of chemical tests for fecal occult blood with an emphasis on false-positive reactions
74. False positive and negative Hemoccult reactions on a normal diet and effect of diet restriction
75. Hemoccult stool test. False negative results due to storage of specimens
76. A comparison of fecal occult-blood tests for colorectal cancer screening
77. Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer
78. Selection criteria in colorectal cancer screening
79. Hemoccult screening for colorectal cancer: The effect of dietary restriction on compliance
80. A comparative study of fecal occult blood tests for early detection of gastrointestinal pathology
81. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas
82. Coloscreen VPI test kit evaluated for detection of fecal occult blood
83. Valeur du test au guaiac pour le depistage des tumeurs colorectales
84. The 'Hemo Quant' test: A specific and quantitative determination of heme [hemoglobin] in feces and other materials
85. An immunofluorescent test for fecal occult blood
86. Immunochemical detection of human blood in feces
87. Evaluation of an immunological test for occult bleeding from colorectal neoplasia
88. Ultrasensitive latex-agglutination test for the specific immunochemical detection and quantitation of fecal blood loss
89. Immunochemical detection of fecal occult blood - The fecal punch-disc test. A new non-invasive screening test for colorectal cancer
90. Rapid immunochemical detection of fecal occult blood by use of a latex-agglutination test
91. Immunochemical detection of fecal occult blood
92. An immunological test for fecal occult blood by counter immunoelectrophoresis
93. Immunochemical confirmation of gastrointestinal bleeding
94. HemoQuant, a new quantitative assay for fecal hemoglobin. Comparison with Hemoccult
95. Improved screening for colorectal cancer by immunological detection of occult blood
96. Ein neuer Latex-Agglutinationstest zum immunologischen Nachweis von okkultem Blut im Stuhl
97. Immunological detection of occult blood in bowel cancer patients
98. A qualitative agar gel immunoprecipitin [IP] test for detection of fecal occult human hemoglobin
99. Immunological detection of fecal occult blood in colorectal cancer
100. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests
101. Chemical and immunological testing for fecal occult blood
102. Early detection of colorectal cancer. Preliminary report on the prospective value of a combined screening method for occult rectal bleeding
103. Sensitized immunochemical method for the specific detection of human hemoglobin in dried biological samples
104. Evaluation of new occult blood tests for detection of colorectal neoplasia
105. Prevention of colorectal cancer: Guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer
106. Colorectal cancer screening: Clinical guidelines and rationale
107. Report of UICC colorectal cancer screening workshop
108. Participation in colorectal cancer screening: A review
109. Screening for colorectal cancer: Present, past and future
110. Sensitivity, specificity, and predictive value of fecal occult blood testing [Hemoccult II] for colorectal neoplasia in symptomatic patients: A prospective study with total colonoscopy
111. Preference of community physicians for cancer screening guidelines
112. Cost-effectiveness model for colon cancer screening
113. Costs and cost-effectiveness of colorectal cancer prevention and therapy
114. Improving the cost-effectiveness of colorectal cancer screening
115. Hemoccult screening in detecting colorectal neoplasm: Sensitivity, specificity, and predictive value
116. Immunochemical versus guaiac fecal occult blood test in a population based screening program for colorectal cancer
117. Evaluation of the sensitivity of an immunochemical fecal occult blood test for colorectal neoplasia
118. Appearance properties, and origin of altered human hemoglobin in feces
119. Immunochemical detection of human denatured hemoglobin in occult blood
120. Measurement of degraded fecal hemoglobin-heme to estimate gastrointestinal site of occult bleeding. Appraisal of its clinical utility
121. Immunochemical detection of human blood in feces
122. Okkultes Blut im Stuhl: Empfindlicher und spezifischer Nachweis durch immunologische Bestimmung von Human-Albumin und Haemoglobin
123. Immunological determination of fecal hemoglobin and transferrin levels: A comparison with other fecal occult blood tests
124. The usefulness of fecal hemoglobin, albumin and α-1-antitrypsin in detection of gastrointestinal bleeding
125. Double immunochemical screening test [hemoglobin and albumin] for the detection of occult intestinal bleeding
126. Fecal degradation of hemoglobin: Effect on an immunochemical test for occult blood
127. HemoSelect vs. Hemoccult II in the diagnosis of colorectal neoplasms: A multicenter trial
128. Laboratory study on occult gastrointestinal bleedings: Differential diagnostic method for the parallel study of intact and fragmented hemoglobin
129. Screening for colorectal cancer with an immunological fecal occult blood test: 2 Year follow-up
130. Fecal lactoferrin a novel marker of colorectal cancer in rats, a longitudinal in vivo study
131. Fecal calprotectin: A novel test for the diagnosis of colorectal cancer?
132. Fecal marker variability in colorectal cancer: Calprotectin versus hemoglobin
133. The potential role or fecal carbonic anhydrase II in screening for colorectal cancer
134. Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer
135. A test for detection of colorectal cancer
136. A simple mucus test for cancer screening
137. Serum ferritin. Screening test for colorectal cancer?
138. Urinary N1-acetylspermidine and N8-acetylspermidine excretion in normal humans and in patients with colorectal cancer
139. Biophysical differentiation between lymphocytes from healthy donors, patients with malignant diseases and other disorders
140. Detection of colon cancer by monitoring the intracellular fluorescin fluorescence polarization changes in lymphocytes
141. Aberrant expression of MUC5AC and MUC6 gastrin mucin genes in colorectal polyps
142. Colorectal cancer: Evidence for distinct genetic categories based on proximal or distal tumor location
143. Human leukocyte antigens as genetic markers in colorectal carcinoma
144. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer
145. Lessons from hereditary colorectal cancer
146. Genetic testing in families with hereditary non-polyposis colon cancer
147. Genetic, natural history, tumor spectrum, and pathology of hereditary non-polyposis colon cancer: An updated review
148. Biochemical and genetic screening of colorectal cancer
149. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumor
150. High frequency of detecting amplifiable DNA in stools of apparently normal individuals
151. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool